3.84
+0(+0.00%)
Currency In USD
| Previous Close | 3.84 |
| Open | 3.86 |
| Day High | 3.95 |
| Day Low | 3.8 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 55,777 |
| Average Volume | 320,725 |
| Market Cap | 36.7M |
| PE | -2.46 |
| EPS | -1.56 |
| Moving Average 50 Days | 3.43 |
| Moving Average 200 Days | 2.31 |
| Change | 0 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $37.83 as of December 24, 2025 at a share price of $3.84. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $590.77 as of December 24, 2025 at a share price of $3.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical compan
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing of SAB-142 in an outpatient setting for the treatme
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today annou